Background Sacubitril/valsartan (S/V) demonstrated significant effects in improving left
ventricular performance and remodeling in patients with heart failure with reduced ejection …

Background: Patients with left ventricular (LV) systolic dysfunction after myocardial infarction
are at a high risk of developing heart failure. The addition of neprilysin inhibition to renin …

Pulmonary hypertension due to left heart disease (PH-LHD) represents approximately 65-
80% of all patients with PH. The progression, prognosis, and mortality of individuals with left …

Background and Objectives: In addition to left ventricular (LV) functions, right ventricular
(RV) functions and pulmonary arterial stiffness (PAS) may be adversely affected in patients …

In terms of sacubitril/valsartan (S/V)-induced changes in heart failure with reduced ejection
fraction (HFrEF) via three-dimensional (3D) transthoracic echocardiography (TTE) and S/V …

Aims ARIADNE aimed to assess the association between effects of sacubitril/valsartan and
no sacubitril/valsartan treatment and clinical characteristics, functional capacity, and clinical …

Aim Sacubitril/valsartan treatment reduces mortality and hospitalizations in heart failure with
reduced ejection fraction but has limited application in hypertrophic cardiomyopathy (HCM) …

(1) Background: Previous studies showed left ventricular (LV) and left atrial (LA)
improvement and reverse remodeling after therapy with Sacubitril/Valsartan (S/V) in patients …

Aims The angiotensin receptor‐neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val)
demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all …

Background Observational studies have demonstrated that treatment with
sacubitril/valsartan may improve left ventricular (LV) systolic and diastolic function in …